Raymond E. Cabillot Sells 3,624 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,624 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $46.66, for a total transaction of $169,095.84. Following the transaction, the director now directly owns 356,022 shares in the company, valued at $16,611,986.52. The trade was a 1.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Pro-Dex Stock Performance

NASDAQ:PDEX opened at $45.00 on Wednesday. The firm has a market capitalization of $146.66 million, a PE ratio of 29.22 and a beta of 0.56. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The firm’s fifty day simple moving average is $48.12 and its 200 day simple moving average is $32.49.

Institutional Investors Weigh In On Pro-Dex

A number of hedge funds have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the period. Renaissance Technologies LLC grew its holdings in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares during the last quarter. Bard Associates Inc. increased its position in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after acquiring an additional 2,296 shares during the period. 15.28% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th. Ascendiant Capital Markets upped their target price on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.